DE69531501T3 - Kombinierte meningitis-vakzine - Google Patents
Kombinierte meningitis-vakzine Download PDFInfo
- Publication number
- DE69531501T3 DE69531501T3 DE69531501T DE69531501T DE69531501T3 DE 69531501 T3 DE69531501 T3 DE 69531501T3 DE 69531501 T DE69531501 T DE 69531501T DE 69531501 T DE69531501 T DE 69531501T DE 69531501 T3 DE69531501 T3 DE 69531501T3
- Authority
- DE
- Germany
- Prior art keywords
- vaccine
- hib
- menc
- conjugate
- vaccine according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940014135 meningitis vaccine Drugs 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 claims abstract description 58
- 229920001542 oligosaccharide Polymers 0.000 claims description 35
- 150000002482 oligosaccharides Chemical class 0.000 claims description 28
- 229960000814 tetanus toxoid Drugs 0.000 claims description 10
- 206010070834 Sensitisation Diseases 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000008313 sensitization Effects 0.000 claims description 8
- 229940032024 DPT vaccine Drugs 0.000 claims description 7
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 6
- 229940001442 combination vaccine Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 101710116435 Outer membrane protein Proteins 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 abstract description 4
- 201000009904 bacterial meningitis Diseases 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 17
- 229940031670 conjugate vaccine Drugs 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 15
- 206010013023 diphtheria Diseases 0.000 description 13
- 102100021503 ATP-binding cassette sub-family B member 6 Human genes 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 241000606768 Haemophilus influenzae Species 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000002096 anti-tetanic effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010043376 Tetanus Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940047650 haemophilus influenzae Drugs 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- -1 Aminosäurekopolymere Chemical class 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000116710 Ferula foetidissima Species 0.000 description 2
- 206010061190 Haemophilus infection Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940127241 oral polio vaccine Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000010899 haemophilus infectious disease Diseases 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422096A GB9422096D0 (en) | 1994-11-02 | 1994-11-02 | Combined meningitis vaccine |
| GB9422096 | 1994-11-02 | ||
| PCT/IB1995/001006 WO1996014086A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE69531501D1 DE69531501D1 (de) | 2003-09-18 |
| DE69531501T2 DE69531501T2 (de) | 2004-06-24 |
| DE69531501T3 true DE69531501T3 (de) | 2008-11-13 |
Family
ID=10763774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69531501T Expired - Lifetime DE69531501T3 (de) | 1994-11-02 | 1995-11-02 | Kombinierte meningitis-vakzine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6251401B1 (https=) |
| EP (3) | EP2204185A1 (https=) |
| JP (3) | JP3989951B2 (https=) |
| AT (1) | ATE246936T1 (https=) |
| CA (2) | CA2204277C (https=) |
| CY (1) | CY2423B1 (https=) |
| DE (1) | DE69531501T3 (https=) |
| DK (1) | DK0789587T4 (https=) |
| ES (1) | ES2204967T5 (https=) |
| GB (1) | GB9422096D0 (https=) |
| PT (1) | PT789587E (https=) |
| WO (1) | WO1996014086A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US6048527A (en) | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
| ES2166097T5 (es) | 1996-08-27 | 2007-03-16 | Novartis Vaccines And Diagnostics, Inc. | Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. |
| EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| ATE372376T1 (de) * | 1997-05-28 | 2007-09-15 | Novartis Vaccines & Diagnostic | Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs |
| US20040087020A1 (en) | 1997-05-28 | 2004-05-06 | Chiron S.P.A. | Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin |
| US20070259007A1 (en) * | 1999-10-19 | 2007-11-08 | Kruzel Marian L | Lactoferrin: an adjuvant for vaccines |
| PT1233784E (pt) * | 1999-12-02 | 2008-11-03 | Novartis Vaccines & Diagnostic | Composições e métodos para a estabilização de moléculas biológicas após a liofilização |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| HU227893B1 (en) * | 2000-06-29 | 2012-05-29 | Glaxosmithkline Biolog Sa | Vaccine compositions |
| CN1306956C (zh) | 2001-04-17 | 2007-03-28 | 希龙公司 | 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物 |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| MXPA04011249A (es) * | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| ES2461350T3 (es) | 2003-01-30 | 2014-05-19 | Novartis Ag | Vacunas inyectables contra múltiples serogrupos de meningococos |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| CN103357002A (zh) | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CA2688268A1 (en) * | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
| WO2009050586A1 (en) * | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| EP3067048B1 (en) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| KR101594228B1 (ko) | 2010-08-23 | 2016-02-15 | 와이어쓰 엘엘씨 | 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제 |
| NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX359256B (es) | 2012-03-09 | 2018-09-19 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| AU2016221318B2 (en) | 2015-02-19 | 2020-06-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP4034157A1 (en) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4451446A (en) * | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5371197A (en) * | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US5628496A (en) | 1995-06-07 | 1997-05-13 | Avm, Inc. | Pneumatic spring |
| US6048527A (en) * | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
-
1994
- 1994-11-02 GB GB9422096A patent/GB9422096D0/en active Pending
-
1995
- 1995-11-02 AT AT95935550T patent/ATE246936T1/de active
- 1995-11-02 WO PCT/IB1995/001006 patent/WO1996014086A1/en not_active Ceased
- 1995-11-02 EP EP10075114A patent/EP2204185A1/en not_active Withdrawn
- 1995-11-02 DE DE69531501T patent/DE69531501T3/de not_active Expired - Lifetime
- 1995-11-02 CA CA002204277A patent/CA2204277C/en not_active Expired - Fee Related
- 1995-11-02 EP EP95935550A patent/EP0789587B2/en not_active Expired - Lifetime
- 1995-11-02 ES ES95935550T patent/ES2204967T5/es not_active Expired - Lifetime
- 1995-11-02 US US08/836,080 patent/US6251401B1/en not_active Expired - Lifetime
- 1995-11-02 JP JP51517596A patent/JP3989951B2/ja not_active Expired - Fee Related
- 1995-11-02 PT PT95935550T patent/PT789587E/pt unknown
- 1995-11-02 CA CA2689871A patent/CA2689871A1/en not_active Abandoned
- 1995-11-02 EP EP03075069A patent/EP1312377A3/en not_active Withdrawn
- 1995-11-02 DK DK95935550T patent/DK0789587T4/da active
-
2004
- 2004-01-30 CY CY0400008A patent/CY2423B1/xx unknown
-
2007
- 2007-03-27 JP JP2007083117A patent/JP4871770B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-21 JP JP2010236921A patent/JP2011016850A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0789587A1 (en) | 1997-08-20 |
| JP2011016850A (ja) | 2011-01-27 |
| GB9422096D0 (en) | 1994-12-21 |
| CY2423B1 (en) | 2004-11-12 |
| DE69531501T2 (de) | 2004-06-24 |
| EP2204185A1 (en) | 2010-07-07 |
| EP2204185A8 (en) | 2010-10-27 |
| WO1996014086A1 (en) | 1996-05-17 |
| JP3989951B2 (ja) | 2007-10-10 |
| PT789587E (pt) | 2003-12-31 |
| EP1312377A3 (en) | 2004-02-04 |
| DK0789587T4 (da) | 2008-08-04 |
| JP2007169302A (ja) | 2007-07-05 |
| ATE246936T1 (de) | 2003-08-15 |
| CA2204277A1 (en) | 1996-05-17 |
| JP4871770B2 (ja) | 2012-02-08 |
| EP0789587B1 (en) | 2003-08-13 |
| DK0789587T3 (da) | 2003-12-01 |
| ES2204967T5 (es) | 2008-07-01 |
| ES2204967T3 (es) | 2004-05-01 |
| CA2204277C (en) | 2010-02-02 |
| CA2689871A1 (en) | 1996-05-17 |
| DE69531501D1 (de) | 2003-09-18 |
| US6251401B1 (en) | 2001-06-26 |
| JPH10509701A (ja) | 1998-09-22 |
| EP0789587B2 (en) | 2008-04-02 |
| EP1312377A2 (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69531501T3 (de) | Kombinierte meningitis-vakzine | |
| DE69708318T3 (de) | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung | |
| DE3787995T2 (de) | Immunogen Konjugate. | |
| DE69934225T2 (de) | Kombinierte meningitis b/c impfstoffe | |
| DE60038166T2 (de) | Impfstoff gegen bakterielle antigene | |
| DE3853854T2 (de) | Vakzin gegen Neisseria meningitidis Gruppe-B, Gammaglobulin und Transferfaktor. | |
| DE69032806T2 (de) | Verfahren zur isolierung und reinigung von rezeptoren für transferrin und lactoferrin von bakterien und herstellung von impfstoffen, die sie enthalten | |
| DE69829400T2 (de) | Passive immunisierung gegen durch clostridium difficile verursachte krankheit | |
| DE69518978T2 (de) | Gruppe a streptokokkenpolysaccharide immunogen-zusammensetzungen und verfahren | |
| DE69423383T2 (de) | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken | |
| DE69118389T2 (de) | Verbesserte vakzinzusammensetzung | |
| DE69627652T2 (de) | Verbesserte meningokokken polysaccharid-konjugat vakzine | |
| DE69113564T2 (de) | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. | |
| DE69111168T2 (de) | Verbesserte Vakzine auf der Basis von Oligosaccharid-Konjugaten. | |
| DE69624726T2 (de) | Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen | |
| DE69631835T3 (de) | Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten | |
| EP1144001A2 (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
| DE69330464T2 (de) | Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe | |
| DE3911442A1 (de) | Impfstoff-praeparation | |
| DE69231663T2 (de) | Polysaccharid-protein-konjugate | |
| CH678394A5 (https=) | ||
| DE69226944T2 (de) | Darstellung und verwendung von mit formalin abgetöteten e. coli bakterien, die das kolonie-faktor-antigen (cfa) expremieren zur impfung gegen das die darminfektion/diarrhoe in menschen auslösende darmbakterium e. coli | |
| DE60019726T2 (de) | Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans | |
| DE69131525T2 (de) | Pasteurella multocida toxoid enthaltende impfstoffe | |
| PARKE JR | Capsular polysaccharide of Haemophilus influenzae type b as a vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: CHIRON S.R.L., SIENA, IT |
|
| 8363 | Opposition against the patent | ||
| 8366 | Restricted maintained after opposition proceedings | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIEN, IT |